Evolv Technologies Holdings, Inc.
EVLV Nasdaq Computer Peripheral Equipment, Nec Financials FY2020βFY2025
What Evolv Technologies Holdings, Inc. does
No business description yet.
- Legal name
- Evolv Technologies Holdings, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Mar 10, 2026
- Accession Β· CIK
- 0001805385-26-000012
0001805385
Revenue and margins
Evolv Technologies Holdings, Inc. had $146M of revenue in fiscal 2025, up 40.5% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was β in fiscal 2025, β of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Evolv Technologies Holdings, Inc. returned β to shareholders in fiscal 2025. The diluted share count rose 7.6%.
Balance sheet
Cash, debt and the ratios that show how comfortably Evolv Technologies Holdings, Inc. can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $307M | $230M | $118M | $51.9M | $69.0M |
| Debt incl. finance leases | $9.9M | $29.7M | $0.0M | $0.0M | $28.6M |
| Debt / equity | 0.0x | 0.1x | 0.0x | 0.0x | 0.2x |
| Interest coverage | β9.1x | β144.6x | β137.7x | β | β28.0x |
| Current ratio | 13.6x | 4.9x | 2.1x | 1.3x | 1.2x |
| Quick ratio | 13.5x | 4.7x | 2.0x | 1.1x | 1.2x |
| Total assets | $363M | $344M | $297M | $268M | $304M |
| Total liabilities | $72.6M | $118M | $153M | $150M | $185M |
| Shareholders' equity | $290M | $227M | $144M | $118M | $119M |
| Net debt (β = net cash) | β$298M | β$200M | β$118M | β$51.9M | β$40.4M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β |
| F-score | β / 3 | 3 / 9 | 2 / 9 | 4 / 9 | 4 / 9 | 4 / 9 |
| Accruals ratio | β22.2% | 23.9% | β3.4% | β30.6% | β8.2% | β18.1% |
| Altman Z'' | β26.64 | 7.77 | 2.57 | β2.31 | β4.95 | β3.93 |
6 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $5.4M | $23.4M | $52.7M | $79.6M | $104M | $146M |
| Gross profit | $1.3M | $4.0M | $1.4M | $31.9M | $59.5M | $75.3M |
| Research and development | $15.6M | $11.5M | $18.5M | $24.5M | $23.4M | $20.6M |
| Operating income | β$28.0M | β$55.3M | β$103M | β$90.1M | β$82.3M | β$48.5M |
| Interest expense | $0.3M | $6.1M | $0.7M | $0.7M | $0.0M | $1.7M |
| Pretax income | β$27.4M | β$10.9M | β$86.8M | β$108M | β$54.0M | β$33.1M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.1M | $0.0M | $0.1M |
| Net income | β$28.4M | β$10.9M | β$86.8M | β$108M | β$54.0M | β$33.1M |
| Net income to common | β$27.4M | β$10.9M | β$86.8M | β$108M | β$54.0M | β$33.1M |
| Diluted EPS | β$3.18 | β$0.15 | β$0.60 | β$0.72 | β$0.34 | β$0.20 |
| Diluted shares | 0.01B | 0.07B | 0.14B | 0.15B | 0.16B | 0.17B |
| Cash flow | ||||||
| Cash from operations | β$23.6M | β$56.8M | β$74.7M | β$9.8M | β$30.9M | $18.7M |
| Capital expenditure | $6.3M | $16.6M | β | β | β | β |
| Free cash flow | β$29.9M | β$73.3M | β | β | β | β |
| Depreciation and amortization | $1.1M | $2.9M | $5.4M | $9.7M | $17.4M | $24.3M |
| Stock-based compensation | $1.6M | $9.6M | $22.5M | $24.1M | $24.8M | $21.1M |
| Balance sheet | ||||||
| Cash and short-term investments | $4.7M | $307M | $230M | $118M | $51.9M | $69.0M |
| Total debt | $16.4M | $9.9M | $29.7M | $0.0M | $0.0M | $28.6M |
| Current assets | $9.8M | $331M | $289M | $173M | $121M | $151M |
| Current liabilities | $12.6M | $24.3M | $58.9M | $81.3M | $96.7M | $123M |
| Inventory | $1.6M | $2.9M | $12.4M | $10.3M | $17.0M | $9.3M |
| Property and equipment, net | $10.1M | $23.8M | $44.7M | $113M | $124M | $128M |
| Total assets | $21.8M | $363M | $344M | $297M | $268M | $304M |
| Total liabilities | $30.7M | $72.6M | $118M | $153M | $150M | $185M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | β$84.8M | $290M | $227M | $144M | $118M | $119M |
| Margins | ||||||
| Gross margin | 24.6% | 17.2% | 2.7% | 40.1% | 57.2% | 51.6% |
| Operating margin | β521.2% | β236.3% | β195.3% | β113.2% | β79.2% | β33.2% |
| EBITDA margin | β501.4% | β223.9% | β185.0% | β101.0% | β62.5% | β16.5% |
| Net margin | β528.3% | β46.5% | β164.6% | β135.8% | β52.0% | β22.7% |
| FCF margin | β555.0% | β313.5% | β | β | β | β |
| Returns | ||||||
| Return on capital | β | β | β306.7% | β276.9% | β99.0% | β48.5% |
| Return on capital employed | β307.6% | β16.3% | β36.1% | β41.7% | β48.0% | β26.7% |
| Return on equity | β | β10.6% | β33.6% | β58.3% | β41.3% | β28.0% |
| Return on assets | β130.6% | β5.7% | β24.5% | β33.7% | β19.1% | β11.6% |
| Return on tangible equity | β | β3.8% | β38.3% | β75.0% | β45.9% | β27.7% |
| Growth | ||||||
| Revenue growth | β | 334.7% | 125.4% | 50.9% | 30.5% | 40.5% |
| Share count change | β | 702.3% | 100.7% | 3.7% | 5.0% | 7.6% |
| Financial health | ||||||
| Debt / equity | β | 0.0x | 0.1x | 0.0x | 0.0x | 0.2x |
| Interest coverage | β88.8x | β9.1x | β144.6x | β137.7x | β | β28.0x |
| Current ratio | 0.8x | 13.6x | 4.9x | 2.1x | 1.3x | 1.2x |
| Quick ratio | 0.6x | 13.5x | 4.7x | 2.0x | 1.1x | 1.2x |
| Capital allocation | ||||||
| Capex / revenue | 116.4% | 70.8% | β | β | β | β |
| Stock comp / revenue | 29.3% | 41.0% | 42.7% | 30.3% | 23.8% | 14.5% |
| Quality scores | ||||||
| Piotroski F-score | β | 3.0 | 2.0 | 4.0 | 4.0 | 4.0 |
| Altman Z'' | β26.6 | 7.8 | 2.6 | β2.3 | β4.9 | β3.9 |
| Accruals ratio | β22.2% | 23.9% | β3.4% | β30.6% | β8.2% | β18.1% |
Source: SEC EDGAR XBRL filings (CIK 0001805385). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.